Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21626519 | 0.69 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL11230782 | 0.67 | GAA (0.36) | GAA | |
| SCHEMBL9918125 | 0.64 | CYP2D6 (0.32) | GAA | |
| SCHEMBL9820126 | 0.64 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL9918124 | 0.63 | CYP2D6 (0.37) | GAA | |
| SCHEMBL4817167 | 0.60 | APEX1 (0.32) | GAA | |
| SCHEMBL22404379 | 0.59 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL10111451 | 0.59 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL2737388 | 0.57 | — | — | |
| SCHEMBL681140 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660286-B2 | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products | EPICENTRX, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20200022952-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | EPICENTRX, INC. | 2020-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660286-B2 | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products | HBB, HBG2, HBZ | GAA 2990/4885SMN1; SMN2 838/4885 |
| US-20200022952-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | HBB, HBG2, HBZ | GAA 2990/4885SMN1; SMN2 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.